Planet 13 Announces Full Year 2020 Financial Results and Q1 2021 Revenue

Rhea-AI Summary

Planet 13 reported Q1 2021 revenue of $23.8 million with $9.7 million in March 2021, marking a significant recovery in Las Vegas post-COVID. In 2020, total revenue reached $70.5 million, representing a 10.8% year-over-year increase. Despite challenges, the company maintained an 8.2% market share in Nevada cannabis dispensary revenue. However, the net loss widened to $7.9 million in 2020 from $6.7 million in 2019, reflecting rising operating costs and decreased gross profit margin.

Positive

• Q1 2021 revenue shows strong recovery with $23.8 million.
• March 2021 revenue set a new single month record at $9.7 million.
• Year-over-year revenue increased by 10.8% in 2020.

Negative

• Net loss increased to $7.9 million in 2020 from $6.7 million in 2019.
• Gross profit margin decreased from 57.3% to 48.5% in 2020.
• Operating expenses rose by 4.3% to $28.0 million in 2020.

• Q1 2021 Revenue of $23.8 million, including $9.7 million in March
• 2020 Revenue of $70.5 million
• Planet 13 accounted for 8.2% of all Nevada cannabis dispensary revenue in Q4
• 2020 EBITDA of $8.9 million

All figures are reported in United States dollars ($) unless otherwise indicated

LAS VEGAS, NV / ACCESSWIRE / April 5, 2021 / Planet 13 Holdings Inc. (CSE:PLTH) (OTCQB:PLNHF) ("Planet 13" or the "Company"), a leading vertically-integrated Nevada cannabis company, today announced its financial results for the three-month and twelve-month period ended December 31, 2020. Planet 13's financial statements are prepared in accordance with International Financial Reporting Standards ("IFRS").

"Based on our performance in March 2021, it is clear that Las Vegas is back." Said Larry Scheffler, Co-CEO of Planet 13. "We dwarfed our single month record with $9.7 million in revenue in March, and we believe that as more people get vaccinated and Las Vegas continues to open, revenue will continue to increase. Looking back on 2020, we weathered the perfect storm of COVID-19 and the resulting 55% decrease in tourism and still increased revenue year over year, generating over $70 million while maintaining our share of the Nevada market."

"With the rapid turn-around we've seen in Q1 and especially in March, it is clear that the improvements we made over the last year will pay dividends as normalcy returns to Las Vegas," commented Bob Groesbeck, Co-CEO of Planet 13. "With tourism back on track, the SuperStore is performing well. Furthermore, our local-focused offerings including Medizin, curbside and delivery, and wholesale are helping us take a greater share of that market. Outside of Las Vegas, the Orange County SuperStore in California is on track and on budget for our projected opening in July. We poured everything we learned from two years running the greatest cannabis store in the world, into our Orange County location and are confident that this store will redefine the cannabis retail experience in California."

Financial Highlights - Q4 - 2020

Operating Results

All comparisons below are to the quarter ended December 31, 2019, unless otherwise noted

• Revenues were $20.1 million as compared to $16.5 million, an increase of 21.8%
• Gross profit before biological adjustments was $7.5 million or 37.1% as compared to $9.4 million or 57.1%
• Operating expenses, excluding non-cash compensation expense and depreciation and amortization, was $8.0 million as compared to $7.1 million, an increase of 13.1%
• Net loss before taxes of $1.2 million as compared to a net loss of $0.9 million
• Net loss of $2.9 million as compared to a net loss of $2.6 million
• Adjusted EBITDA of $0.3 million as compared to Adjusted EBITDA of $2.6 million

Balance Sheet

All comparisons below are to December 31, 2019, unless otherwise noted

• Cash of $79.0 million as compared to $12.8 million
• Total assets of $150.0 million as compared to $62.9 million
• Total liabilities of $29.3 million as compared to $21.6 million

Financial Highlights - Full Year - 2020

All comparisons below are to the year ended December 31, 2019, unless otherwise noted

• Revenues were $70.5 million as compared to $63.6 million, an increase of 10.8%
• Gross profit before biological adjustments was $34.2 million or 48.5% as compared $36.5 million or 57.3%
• Operating expenses, excluding non-cash compensation expense, were $28.0 million as compared to $26.8 million, an increase of 4.3%
• Net loss before taxes of $0.8 million as compared to a net profit of $0.5 million
• Net loss of $7.9 million as compared to a net loss of $6.7 million
• Adjusted EBITDA of $8.9 million as compared to Adjusted EBITDA of $10.2 million

Q4 Highlights and Recent Developments

For a more comprehensive overview of these highlights and recent developments, please refer to Planet 13's Management's Discussion and Analysis of the Financial Condition and Results of Operations for the Three Months and Twelve Months Ended December 31, 2020 (the "MD&A").

• On October 13, 2020, Planet 13 announced the addition of non-cannabis retail space to the Las Vegas SuperStore.
• On October 19, 2020, Planet 13 announced expanding the dispensary floor of the Las Vegas SuperStore.
• On October 19, 2020, Planet 13 announced a CDN$20 million bought deal public offering.
• On October 20, 2020, Planet 13 announced an upsize to bought deal public offering to CDN$25 million.
• On November 5, 2020, Planet 13 announced the closing of a CDN$28.8 million bought deal public offering.
• On November 20, 2020, Planet 13 announced opening the Medizin dispensary.
• On November 27, 2020, Planet 13 announced second closing under its asset purchase agreement.
• On December 10, 2020, Planet 13 announced winning multiple awards at Las Vegas Jack Herer Cup.
• On January 12, 2021, Planet 13 announced a CDN$50 million bought deal and upsizeing.
• On February 2, 2021, Planet 13 announced closing of CDN$69 million bought deal.
• On February 3, 2021, Planet 13 announced the start of construction on the Orange County SuperStore.
• On March 15, 2021 Planet 13 announced a partnership with Curaleaf Select to open shop-in-shop.

Results of Operations (Summary)

The following tables set forth consolidated statements of financial information for the three-month and twelve-month periods ending December 31, 2020 and December 31, 2019. For further information regarding the Company's financial results for these periods, please refer to the Company's annual financial statements for the period ended December 31, 2020 together with the MD&A, available on Planet 13's issuer profile on SEDAR at www.sedar.com and the Company's website https://www.planet13holdings.com.

Adjusted EBITDA

		NV Cannabis Ops				Consolidated				Consolidated								NV Cannabis Ops				Consolidated
		Three Months				Three Months				Three Months								Year				Year				Year
		Ended				Ended				Ended				Percentage				Ended				Ended				Ended				Percentage
		Dec-31-2020				Dec-31-2020				Dec-31-2019				Change				Dec-31-2020				Dec-31-2020				Dec-31-2019				Change
EBITDA
Profit (loss) before taxes			(227,795	)			(1,238,771	)			(914,960	)			35.4	%			4,896,181				(849,268	)			542,664				(256.5	%)
Add back:
Biological asset adjustments			(1,396,910	)			(1,396,910	)			351,080				(497.9	%)			(1,171,616	)			(1,171,616	)			480,181				(344.0	%)
Non-cash share based payments			-				506,501				1,694,370				(70.1	%)			-				2,512,568				4,822,787				(47.9	%)
Depreciation and amortization			1,051,894				1,051,894				900,278				16.8	%			4,155,741				4,155,741				2,845,464				46.0	%
Depreciation included in COGS			517,177				517,177				157,026				229.4	%			1,900,288				1,900,288				472,661				302.0	%
ROU Interest included in COGS			325,718				325,718				35,524								783,318				783,318				121,257
Interest and non-operating expense (income)			538,047				538,047				329,291				63.4	%			1,579,784				1,579,792				954,960				65.4	%
EBITDA			808,131				303,656				2,552,609				(88.1	%)			12,143,696				8,910,823				10,239,974				(13.0	%)
Margin			4.0	%			1.5	%			15.4	%							17.2	%			12.6	%			16.1	%

Expressed in USD$		Three Months				Three Months								Year				Year
		Ended				Ended				Percentage				Ended				Ended				Percentage
		Dec-31-2020				Dec-31-2019				Change				Dec-31-2020				Dec-31-2019				Change
Revenue
Revenues, net of discounts			20,139,944				16,540,324				21.8	%			70,491,280				63,595,036				10.8	%
Cost of Goods Sold			(12,670,805	)			(7,098,908	)			78.5	%			(36,291,251	)			(27,139,658	)			33.7	%
Gross Profit, Before Biological Asset Adjustment			7,469,139				9,441,416				(20.9	%)			34,200,029				36,455,378				(6.2	%)
Gross Profit Margin %			37.1	%			57.1	%							48.5	%			57.3	%
Realized fair value amounts included in COGS			377,903				(695,361	)			(154.3	%)			(1,104,525	)			(1,500,965	)			(26.4	%)
Unrealized fair value gain on growth of biological assets			1,019,007				344,281				196.0	%			2,276,141				1,020,784				123.0	%
Gross profit			8,866,049				9,090,336				(2.5	%)			35,371,645				35,975,197				(1.7	%)
Gross Profit Margin %			44.0	%			55.0	%							50.2	%			56.6	%
Expenses
General and Administrative			7,386,914				5,351,056				38.0	%			24,667,172				20,269,839				21.7	%
Sales and Marketing			621,464				1,730,301				(64.1	%)			3,305,640				6,539,483				(49.5	%)
Depreciation and Amortization			1,051,894				900,278				16.8	%			4,155,741				2,845,464				46.0	%
Share based payments			506,501				1,694,370				(70.1	%)			2,512,568				4,822,787				(47.9	%)
Total Expenses			9,566,773				9,676,005				(1.1	%)			34,641,121				34,477,573				0.5	%
Income (Loss) From Operations			(700,724)				(585,669)				19.6	%			730,524				1,497,624				(51.2	%)
Other (Income) Expense:
Interest Expense, net			504,692				404,332				24.8	%			1,796,641				1,306,876				37.5	%
Realized Foreign Exchange gain (loss)			-				-			na					-				(1,141	)			(100.0	%)
Other expense (income)			33,355				(75,041	)			(144.4	%)			(216,849	)			(350,775	)			(38.2	%)
Total Other Expense (Income)			538,047				329,291				63.4	%			1,579,792				954,960				65.4	%
Income (loss) for the period before tax			(1,238,771)				(914,960)				35.4	%			(849,268)				542,664				(256.5	%)
Provision for income tax (current and deferred)			1,666,546				1,662,213				0.3	%			7,092,257				7,200,997				(1.5	%)
Income (Loss) for the period			(2,905,317)				(2,577,173)				12.7	%			(7,941,525)				(6,658,333)				19.3	%
Other Comprehensive Income (Loss)
Items that may be reclassified subsequently to profit/loss
Foreign exchange translation adjustment			333,528				(24,607	)							128,585				195,213
Net Comprehensive Income (Loss) for the period			(2,571,789)				(2,601,780)								(7,812,940)				(6,463,120)
Income (Loss) per share for the period
Basic and fully diluted loss per share		$	(0.02)			$	(0.02)							$	(0.05)			$	(0.05)
Weighted Average Number of Shares Outstanding
Basic and fully diluted			175,660,734				135,888,982								151,825,439				134,074,476

Outstanding Shares

As of April 5, 2021, the Company had 140,330,574 common shares and 55,232,940 class A convertible, restricted voting shares issued and outstanding for a total of 195,563,514 shares outstanding. There were 184,168 options issued and outstanding of which all have fully vested. There were 9,700,341 warrants outstanding and 912,095 RSU's outstanding of which nil RSUs had fully vested as at the date of this MD&A.

Conference Call

Planet 13 will host a conference call on Monday, April 5, 2021 at 5:00 p.m. EST to discuss its fourth quarter financial results and provide investors with key business highlights. The call will be chaired by Bob Groesbeck, Co-CEO, Larry Scheffler, Co-CEO, and Dennis Logan, CFO.

CONFERENCE CALL DETAILS

Date: April 5, 2021 | Time: 5:00 p.m. EST
Participant Dial-in: Toll Free 877-407-8035 or International 201-689-8035
Replay Dial-in: Toll Free 877-481-4010 or International 919-882-2331
(Available for 2 weeks)
Reference Number: 40511
Listen to webcast: https://bit.ly/393yrjE

Financial Measures

There are measures included in this news release that do not have a standardized meaning under generally accepted accounting principles (GAAP) and therefore may not be comparable to similarly titled measures and metrics presented by other publicly traded companies. The Company includes these measures because it believes certain investors use these measures and metrics as a means of assessing financial performance. EBITDA (earnings before interest, taxes, depreciation and amortization) is calculated as net earnings before finance costs (net of finance income), income tax expense, and depreciation and amortization of intangibles and is a non-GAAP financial measure that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies.

For further inquiries, please contact:

LodeRock Advisors Inc., Planet 13 Investor Relations
mark.kuindersma@loderockadvisors.com
(416) 519-2156 ext. 2230

Bob Groesbeck and Larry Scheffler
Co-Chief Executive Officers
ir@planet13lasvegas.com

About Planet 13

Planet 13 (www.planet13holdings.com) is a vertically integrated cannabis company based in Nevada, with award-winning cultivation, production and dispensary operations in Las Vegas - the entertainment capital of the world. Planet 13's mission is to build a recognizable global brand known for world-class dispensary operations and a creator of innovative cannabis products. Planet 13's shares trade on the Canadian Stock Exchange (CSE) under the symbol PLTH and OTCQX under the symbol PLNHF.

Cautionary Note Regarding Forward-Looking Information

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward looking-statements relate to, among other things, Planet 13's first California location and the timeline for opening of the Santa Ana dispensary.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: final regulatory and other approvals or consents; risks associated with COVID-19 and other infectious diseases presenting as major health issues; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the Nevada and California cannabis market and changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution and sale of cannabis and cannabis related products in the State of Nevada and California; and employee relations. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

The Company is indirectly involved in the manufacture, possession, use, sale and distribution of cannabis in the recreational and medicinal cannabis marketplace in the United States through licensed subsidiary entities in states that have legalized marijuana operations, however, these activities are currently illegal under United States federal law. Additional information regarding this and other risks and uncertainties relating to the Company's business, including COVID-19, are contained under the heading "Risk Factors" and elsewhere in the Company's annual information form dated April 5, 2021 filed on its issuer profile on SEDAR at www.sedar.com.

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

Expressed in United States Dollars		As at				As at
		December 31,				December 31,
		2020				2019
Assets
Current Assets
Cash		$	79,000,850			$	12,814,712
HST receivable			103,445				16,544
Inventories (Note 6)			7,334,717				5,474,004
Biological assets (Note 7)			640,995				514,526
Prepaid expenses and other current assets (Note 11)			2,637,547				3,694,272
Total Current Assets			89,717,554				22,514,058
Property and equipment (Note 8)			32,073,925				30,211,154
Licenses (Note 9)			7,007,362				-
Right of use assets (Note 10)			20,149,721				9,478,733
Long-term deposits and other assets			1,054,443				694,601
			60,285,451				40,384,488
Total Assets		$	150,003,005			$	62,898,546
Liabilities
Current Liabilities
Accounts payable		$	1,683,833			$	864,260
Accrued expenses			2,844,714				1,910,046
Income taxes payable			1,220,652				7,015,606
Notes payable - current portion (Note 12)			884,000				884,000
Total Current Liabilities			6,633,199				10,673,912
Long -term lease liabilities (Note 13)			22,326,077				10,522,377
Other long-term liabilities			28,000				28,000
Deferred tax liability (Note 19)			313,422				379,665
			22,667,499				10,930,042
Total Liabilities			29,300,698				21,603,954
Shareholders' Equity
Share capital (Note 14)			139,177,034				51,986,849
Restricted share units (Note 14)			3,262,351				4,119,485
Warrants (Note 14)			6,972,053				5,961,091
Option reserve (Note 14)			276,081				399,439
Accumulated other comprehensive loss			(479,122	)			(607,707	)
Deficit			(28,506,090	)			(20,564,565	)
Total Shareholders' Equity			120,702,307				41,294,592
Total Liabilities and Shareholders' Equity		$	150,003,005			$	62,898,546

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS)

Expressed in United States Dollars		Three months				Three months				Year				Year
		Ended				Ended				Ended				Ended
		December 31,				December 31,				December 31,				December 31,
		2020				2019				2020				2019
Revenue
Revenues, net of discounts		$	20,139,944			$	16,540,324			$	70,491,280			$	63,595,036
Cost of Goods Sold			(12,670,805	)			(7,098,908	)			(36,291,251	)			(27,139,658	)
Gross Profit before fair value asset adjustment			7,469,139				9,441,416				34,200,029				36,455,378
Realized fair value amounts included in inventory sold			377,903				(695,361	)			(1,104,525	)			(1,500,965	)
Unrealized fair value gain on growth of biological assets			1,019,007				344,281				2,276,141				1,020,784
Gross Profit			8,866,049				9,090,336				35,371,645				35,975,197
Expenses
General and Administrative (Note 15)			7,386,914				5,351,056				24,667,172				20,269,839
Sales and Marketing			621,464				1,730,301				3,305,640				6,539,483
Depreciation and Amortization (Note 8 & 10)			1,051,894				900,278				4,155,741				2,845,464
Share-Based Compensation Expense (Note 14 and Note 18)			506,501				1,694,370				2,512,568				4,822,787
Total Expenses			9,566,773				9,676,005				34,641,121				34,477,573
Income From Operations			(700,724)				(585,669)				730,524				1,497,624
Other Expense:
Interest expense, net			504,692				404,332				1,796,641				1,306,876
Realized foreign exchange loss			-				-				-				(1,141	)
Other income			33,355				(75,041	)			(216,849	)			(350,775	)
Total Other Expense			538,047				329,291				1,579,792				954,960
Income (Loss) before income taxes			(1,238,771)				(914,960)				(849,268)				542,664
Provision for tax - current (Note 19)			1,817,805				1,402,227				7,158,500				7,292,188
Provision for tax - deferred (Note 19)			(151,259	)			259,986				(66,243	)			(91,191	)
Loss for the year		$	(2,905,317)			$	(2,577,173)			$	(7,941,525)			$	(6,658,333)
Other Comprehensive Income
Foreign exchange translation gain			333,528				(24,607	)			128,585				195,213
Net Comprehensive Loss for the year		$	(2,571,789)			$	(2,601,780)			$	(7,812,940)			$	(6,463,120)
Loss per share for the year
Basic and diluted loss per share (Note 16)		$	(0.02)			$	(0.02)			$	(0.05)			$	(0.05)
Weighted Average Number of Common Shares Outstanding
Basic and Diluted			175,660,734				135,888,982				151,825,439				134,074,476

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Expressed in United States Dollars		Year				Year
		Ended				Ended
		December 31,				December 31,
		2020				2019
Operating activities
Net loss for the year		$	(7,941,525	)		$	(6,658,333	)
Add (deduct) non-cash items:
Share based payments (Note 14 and 18)			2,512,568				4,822,787
Depreciation and amortization (Note 8 and 10)			6,056,031				3,607,286
Deferred tax liability			(66,243	)			(91,191	)
Write-off of fixed assets during the year			-				82,882
Non-cash interest expense on ROU Liabilities (Note 13)			2,559,047				1,367,759
Net change in non-cash working capital
HST receivable			(91,533	)			85,287
Inventories (Note 6)			(227,841	)			(151,893	)
Biological assets (Note 7)			(126,469	)			400,651
Prepaid expenses and other assets (Note 11)			1,178,734				(2,426,866	)
Long term deposits and other assets			(359,842	)			(100,262	)
Accounts payable			452,393				(856,462	)
Accrued expenses			934,669				603,902
Income tax payable			(5,794,954	)			4,828,497
Other long-term liabilities			-				28,000
Cash flow provided by (used in) operating activities			(914,965)				5,542,044
Investing activities
Purchase of property, plant and equipment (Note 8)			(4,481,058	)			(16,061,582	)
Purchase of licenses (Note 9)			(3,550,400	)			-
Cash flow used in investing activities			(8,031,458)				(16,061,582)
Financing activities
Issuance of shares on warrant and option exercises (Note 14)			32,871,439				5,030,185
Issuance of shares and warrants on financings			44,464,540				-
Payment on lease liabilities			(2,337,006	)			(1,247,546	)
Cash flow provided by financing activities			74,998,973				3,782,639
Net increase in cash			66,052,550				(6,736,899)
Cash at beginning of the year			12,814,712				19,364,086
Effect of foreign exchange on cash			133,588				187,525
Cash at end of the year		$	79,000,850			$	12,814,712

SOURCE: Planet 13 Holdings Inc.

View source version on accesswire.com:
https://www.accesswire.com/638972/Planet-13-Announces-Full-Year-2020-Financial-Results-and-Q1-2021-Revenue

FAQ

What were Planet 13's Q1 2021 revenue figures?

Planet 13 reported Q1 2021 revenue of $23.8 million, including $9.7 million in March.

What is the financial performance of Planet 13 for the full year 2020?

In 2020, Planet 13 generated $70.5 million in revenue, a 10.8% increase year-over-year.

How did Planet 13's net loss change in 2020?

Planet 13's net loss increased to $7.9 million in 2020 from $6.7 million in 2019.

What market share did Planet 13 hold in Q4 2020?

Planet 13 accounted for 8.2% of all Nevada cannabis dispensary revenue in Q4 2020.

What were the operating expenses for Planet 13 in 2020?

Operating expenses for Planet 13 rose to $28.0 million in 2020, up by 4.3%.